Sign of efficacy and dose levels in phase 1 oncology trials.

<p>Sign of efficacy and dose levels in phase 1 oncology trials.</p

Sign of efficacy and MTD in 317 phase 1 oncology trials.

<p>MTD: dose maximal tolerated dose;</p><p>*: p<0.05.</p><p>The total of trials within the same treatment categories could differ in the different lines because no data concerning MTD was available in 28 trials and because the first sign of efficacy was not linked to a dose-level in 64 trials.</p

Partition of patients.

<p>(*) one patient excluded because progression was defined by increased in tumor marker. Pt: patient.</p

Patient characteristics at progression.

<p>Patient characteristics at progression.</p

Performance of clinical judgment of tumour progression.

<p>Performance of clinical judgment of tumour progression.</p

Baseline characteristics.

<p>Baseline characteristics.</p

90-day-mortality-rates and 95%-confidence intervals according to the predicitve score.

<p>LR-Dev: Low-risk patients among the developpement cohort (score = [0–1]). LR-Val: Low-risk patients among the validation cohort (score = [0–1]). IR-Dev: Intermediate-risk patients among the developpement cohort (score = 2). IR-Val: Intermediate-risk patients among the validation cohort (score = 2). HR-Dev: High-risk patients among the developpement cohort (score = [3–4]). HR-Val: High-risk patients among the validation cohort (score = [3–4]).</p

Predictive score and its performance.

<p>Predictive score and its performance.</p

Patient's characteristics.

<p>Abbreviations: PS = performance status, met. = metastasis, LDH = lactate dehydrogenase, ULN = upper limit of normal, IU: international unit, U:unit.</p

Identification of predictive factors for 90-day-mortality.

<p>Abbreviations: 95%-CI: 95%-confidence intervals, PS = performance status, met. = metastasis, LDH = lactates dehydrogenase, AP = Alkaline phosphatase, ULN = upper limit of normal.</p